Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Carboplatin
Drug ID BADD_D00364
Description Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982.[A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Indications and Usage Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma.[L32253] Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.[L32253]
Marketing Status approved
ATC Code L01XA02
DrugBank ID DB00958
KEGG ID D01363
MeSH ID D016190
PubChem ID 426756
TTD Drug ID D0X7HM
NDC Product Code 0703-4239; 55150-386; 63323-172; 68083-191; 63592-0271; 61703-339; 0703-4244; 0703-4246; 72659-863; 50742-447; 69448-005; 61703-600; 55150-334; 61703-262; 61703-360; 71288-100; 49812-0010; 16729-295; 55150-333; 61703-150; 68083-193; 68554-0084; 68083-190; 68083-192; 53104-7570; 54875-0002; 50742-448; 55150-335; 0703-4248
UNII BG3F62OND5
Synonyms Carboplatin | cis-Diammine(cyclobutanedicarboxylato)platinum II | CBDCA | Paraplatin | Paraplatine | Platinwas | Ribocarbo | Carboplat | Neocarbo | Carbosin | Carbotec | Ercar | JM-8 | JM 8 | JM8 | Nealorin | NSC-241240 | NSC 241240 | NSC241240 | Blastocarb
Chemical Information
Molecular Formula C6H12N2O4Pt
CAS Registry Number 41575-94-4
SMILES C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Asphyxia12.01.08.011; 22.02.02.0010.000783%Not Available
Aspiration22.02.07.0070.000526%
Asthenia08.01.01.0010.009100%Not Available
Astrocytoma17.20.01.002; 16.30.01.0020.000336%Not Available
Ataxia17.02.02.001; 08.01.02.0040.000448%
Atelectasis22.01.02.0010.001086%
Atrial fibrillation02.03.03.0020.002183%
Atrial flutter02.03.03.0030.000448%
Back pain15.03.04.0050.003515%
Blindness06.02.10.003; 17.17.01.0030.000448%Not Available
Blindness cortical06.02.10.004; 17.17.01.017--Not Available
Blindness transient06.02.10.006; 17.17.01.0040.000560%Not Available
Blood bilirubin increased13.03.04.018--
Blood calcium decreased13.11.01.002--Not Available
Blood creatinine decreased13.13.01.003--Not Available
Blood creatinine increased13.13.01.004--
Blood magnesium decreased13.11.01.008--Not Available
Blood potassium decreased13.11.01.010--Not Available
Blood sodium decreased13.11.01.012--Not Available
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Bone pain15.02.01.001--
Bronchospasm22.03.01.004; 10.01.03.0120.002518%
Bronchostenosis22.03.01.0200.000168%
Bundle branch block left02.03.01.0070.000246%Not Available
Burning sensation17.02.06.001; 08.01.09.0290.000918%Not Available
Cachexia16.32.03.011; 14.03.02.001; 08.01.01.0090.000112%Not Available
Capillary leak syndrome24.06.03.001; 08.01.07.0120.000280%
Cardiac arrest02.03.04.0010.001175%
Cardiac failure02.05.01.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 21 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene